Human Amniotic Membrane to Decrease Post Operative Atrial Fibrillation

Safety and Feasibility Human Amniotic Membrane to Decrease Post Operative Atrial Fibrillation After Coronary Artery Bypass Grafting

This study will evaluate the application of hAM at the time of cardiac surgery to decrease inflammation and the subsequent substrate to reduce incidence of post-operative atrial fibrillation. Patients will randomized 1:1 to receive either hAM application or standard of care.

Inclusion Criteria:

• Patients undergoing primary elective CABG at the University of Utah Hospital
• Ability to provided informed consent and follow-up with protocol procedures

Exclusion Criteria:

• Patients in AF at the time of surgery
• Prior history of sternotomy
• Prior history of pericarditis
• Currently on aggressive antiarrhythmic therapy (does not include beta blockers)
• Patients with an implantable cardiac device (pacemaker, ICD, CRT-D)
• Ejection fraction <45%